Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan
dc.authorid | 0000-0002-6937-1470 | en_US |
dc.authorscopusid | 54403988500 | en_US |
dc.authorwosid | DZI-8159-2022 | en_US |
dc.contributor.author | Ersoy Yeşil, Ezgi | |
dc.contributor.author | Yılmaz, Yusuf | |
dc.contributor.author | Yeşil, Atakan | |
dc.contributor.author | Meşe, Meral | |
dc.contributor.author | Kaya, Eda | |
dc.contributor.author | Arı Bakır, Elif | |
dc.date.accessioned | 2023-01-31T15:32:26Z | |
dc.date.available | 2023-01-31T15:32:26Z | |
dc.date.issued | 2023 | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.description.abstract | Background & Aim: Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTR). In this study, we evaluated the prevalence of MAFLD among KTRs, a data that has not been investigated by any clinical study to date. Matherials and Methods: We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as control group through a prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan. Results: Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, CI 95%: 1.039-1.208). Conclusion: MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed. | en_US |
dc.identifier.citation | Ersoy Yeşil, E., Yılmaz, Y., Yeşil, A., Meşe, M., Kaya, E. & Arı Bakır, E. (2023). Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan. Hepatology Forum, 4(1), pp. 14-18. https://doi.org/10.14744/hf.2022.2022.0038 | en_US |
dc.identifier.doi | 10.14744/hf.2022.2022.0038 | en_US |
dc.identifier.endpage | 18 | en_US |
dc.identifier.issn | 1307-5888 | |
dc.identifier.issn | 2757-7392 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | PMID: 36843889 | en_US |
dc.identifier.scopus | 2-s2.0-85164338674 | en_US |
dc.identifier.startpage | 14 | en_US |
dc.identifier.trdizinid | 1179038 | |
dc.identifier.uri | https://doi.org/10.14744/hf.2022.2022.0038 | |
dc.identifier.uri | https://hdl.handle.net/20.500.13055/383 | |
dc.identifier.volume | 4 | en_US |
dc.identifier.wos | WOS:000923480400004 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.indekslendigikaynak.other | ESCI - Emerging Sources Citation Index | en_US |
dc.institutionauthor | Yeşil, Atakan | |
dc.language.iso | en | en_US |
dc.publisher | Kare Publishing | en_US |
dc.relation.ispartof | Hepatology Forum | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Fibroscan | en_US |
dc.subject | Kidney Transplant Recipients | en_US |
dc.subject | Mafld | en_US |
dc.title | Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication |